Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
19 februari, 14:00
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
PR Newswire
GAITHERSBURG, Md., Feb. 19, 2026
GAITHERSBURG, Md. , Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:
Conference call details: | |
Date: | February 26, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, February 26, 2026, until 11:59 p.m. ET, March 5, 2026 |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 9610065# |
Webcast: | ir.novavax.com/events , until March 25, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com
SOURCE Novavax, Inc.
Ämnen i artikeln
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
19 februari, 14:00
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
PR Newswire
GAITHERSBURG, Md., Feb. 19, 2026
GAITHERSBURG, Md. , Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:
Conference call details: | |
Date: | February 26, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, February 26, 2026, until 11:59 p.m. ET, March 5, 2026 |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 9610065# |
Webcast: | ir.novavax.com/events , until March 25, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com
SOURCE Novavax, Inc.
Ämnen i artikeln
Blankningar
Analys
Internationellt
Nvidia
Blankningar
Analys
Internationellt
Nvidia
Marknadsöversikt
1 DAG %
Senast
1 mån
